DIRS.INFO The most relevant business & tech news

☆ This veteran investor's funds have been outperforming since 2006. Here are his top investing tips
▼ + stars: | 2023-06-20 | by ( Weizhen Tan | ) www.cnbc.com time to read: +6 min

Those are the qualities that outperforming portfolio manager Jordan Cvetanovski has looked for in stocks for the past nearly 20 years. Since its inception in 2022 to May 31, his Pella Global Generations Fund has delivered nearly 20%, outperforming its benchmark — the MSCI ACWI (the MSCI's flagship global stock index) — by 7%. As an investor, Cvetanovski, who is based in Sydney, Australia, said he invests only in his own 34-stock fund, the Pella Global Generations Fund. Investing 'won't be as simple as it was' Cvetanovski said his method of investing has stayed "exactly the same" through the years. Following sustainability criteria is one of Pella Global Generations Fund's objectives.

Persons: Jordan Cvetanovski, I've, …, Carmignac, Cvetanovski, IQVIA, there's, Tesla, EVs Organizations: CNBC Pro, Pengana International, Pengana Capital Group, Fund, Generations Fund, Pella Funds, 3i, Adobe, McLennan, Novo Nordisk, UnitedHealth Locations: Pella, Sydney, Australia, China, U.S, Europe

WASHINGTON, April 20 (Reuters) - Use of the drug misoprostol on its own to terminate pregnancies is on the rise in the United States as providers seek a preemptive alternative while a ban on abortion pill mifepristone is being considered in court. Misoprostol is already part of the only medication abortion protocol approved by the U.S. Food and Drug Administration, but only when taken in combination with mifepristone. The drug, which the FDA first approved in 1988 for gastric ulcers, is often prescribed off-label to treat miscarriages or induce abortions. "If providers are forced to stop providing mifepristone, misoprostol alone is also safe and effective," said Dr. Ushma Upadhyay, a public health professor at the University of California, San Francisco. Because misoprostol is approved for medication abortion in the United States as part of the two-drug combination, prescribing it alone to terminate pregnancies would also be considered off-label.

☆ Morning Bid: Volatility stirs
▼ + stars: | 2023-02-10 | by ( ) www.reuters.com time to read: +5 min

World markets end a rough week of confusing and competing narratives in distinctly edgy form, with peculiarly subdued volatility gauges flickering back to life. Both 10 and 30-year yields hit their highest levels in over a month early on Friday. Job shedding in the digital sector continued, with Yahoo's plans to lay off more than 20% of its total workforce. That said, the year-on-year oil price trend continues to be negative, as it's been all year and base effects from last year's price spike around the Ukraine invasion will only deepen that and weigh on headline inflation further. Goldman Sachs lowered its oil price forecasts for this year and next, cutting its Brent 2023 price forecast by $6 to $92 per barrel - still above current levels around $86.

Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. European generic drugmakers say the tender system and regulated prices have fuelled a race to the bottom, and European firms are being undercut by suppliers from Asia. BRUSSELS, WE HAVE A PROBLEMThe European Medicines Agency (EMA) and European Union lawmakers acknowledge there is a problem. Half the generic medicines sold in Spain are priced below 1.60 euros per box or bottle, the country's generics manufacturing association said. But companies with smaller market shares, such as Israel's Teva (TEVA.TA), which has 5% of the region's amoxicillin market according to Medicines for Europe, are constrained.

☆ A flurry of earnings reports, Fed rate hike, signs of a bull market
▼ + stars: | 2023-02-04 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Earnings season continues next week, with Club holdings Linde (LIN), Emerson Electric (EMR) and Walt Disney (DIS) all set to report. Similarly, shares of Meta Platforms (META) have surged over 20% since CEO Mark Zuckerberg reassured investors Wednesday evening that 2023 would be the technology giant's "year of efficiency." The bull case is further supported by continued signs inflation is easing, a still-robust job market and the breadth of market-buying activity since the start of the year. Lastly on Wednesday, the Fed's Federal Open Market Committee raised the federal funds rate by 25 basis points, in line with expectations. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Indian shares set to open higher to track Asia; Q3 results eyed
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: +2 min

At home, IT major Tata Consultancy Services (TCS.NS) was set to report third quarter results after market close. Analysts expect weak Q3 revenue growth for IT services firms, on the back of deteriorating macroeconomic conditions and furloughs in the quarter. Domestic investors bought 10.83 billion rupees worth of shares, as per provisional NSE data. ** Titan Company (TITN.NS): Co reported 12% YoY growth in combined sales in third quarter, driven by festive season. ** Tata Steel (TISC.NS): Company's India crude steel production stood at 5 million tonnes in third quarter, up 4% YoY.

☆ Fund manager says a recession is ‘imminent’ — and names cheap stocks to play it
▼ + stars: | 2022-12-21 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

The yield curve is already signaling that a recession could be on the horizon. I think that's pretty clear," fund manager Steven Glass told CNBC's "Street Signs Asia" Monday. So, we think the bond market suggests that could likely be a recession in probably the next year," Glass added. An inverted yield curve occurs when interest rates on shorter-term U.S. Treasury bonds are higher than longer-term ones. With inflation likely to remain higher-for-longer in the near term and companies facing earnings pressure, Glass said he is focusing on companies with earnings visibility.

☆ Here are some of Credit Suisse's top stock picks heading into 2023
▼ + stars: | 2022-12-14 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Credit Suisse has refreshed its list of top U.S. stock picks. Microsoft is among Credit Suisse's "top of the crop" ideas, along with Discover Financial and Motorola Solutions . Here are 10 of Credit Suisse's top picks: Microsoft is a recurring "top of the crop" pick, chosen by Credit Suisse analysts for its potential to "disproportionately benefit" from the accelerated shift from infrastructure and platform layers to cloud-first roadmaps. Among the newcomers, Ross Stores is one of Credit Suisse's top picks among discount retailers. Credit Suisse's price target is about 4% from Tuesday's closing price.

☆ Home delivery of medications can help improve access, especially when time is tight
▼ + stars: | 2022-12-08 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +7 min

As the supply of Paxlovid has grown, efforts have been made to improve timely, equitable access to the treatment. Transportation is one significant barrier to health care access for many people, experts say, but creating equitable outcomes will involve a much more comprehensive approach. The initiative is meant to increase access to Covid-19 treatment, particularly for those in socially vulnerable or medically underserved communities. “It’s a combination of things that prevent access to care,” said Werner, whose research has focused on health equity. And those may be the ones that I think would be ripe for this kind of home-based delivery system,” Werner said.

One of the biggest makers of generic drugs, Israeli-based Teva said it aims eventually to secure a 10% global market share of biosimilars. A division of Novartis (NOVN.S), Sandoz is currently the second biggest player after Pfizer Inc (PFE.N) in the biosimilar market by gross sales globally, per IQVIA data, cited by Sandoz. Sandoz launched eight biosimilar drugs between 2017 and 2021, including a version of Bristol-Myers’ multiple myeloma drug Revlimid. The analysis projected the value of the global biosimilar market could more than triple to an estimated $74 billion by 2030. Sandoz and Teva are both working on biosimilars for Humira.

☆ Analysts think the biggest stock winners this week are set to cool off — except two
▼ + stars: | 2022-10-28 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Analysts expect that this week's biggest winners will cool off from here, with the notable exception of just two stocks: Centene and IQVIA. However, the majority of those names are set for single-digit gains, according to consensus estimates on FactSet. What's more, the health care stock has a buy rating from a majority of analysts, and is forecasted to advance nearly 20%. Another health care stock, IQVIA , jumped 14% this week. Enphase surpassed profit and sales expectations this week, according to consensus estimates from FactSet.

The Food and Drug Administration on Wednesday confirmed a nationwide shortage of the attention-deficit/hyperactivity disorder medication Adderall, more than two months after some pharmacies reported difficulties filling prescriptions. The shortage affects the immediate-release form of Adderall, a stimulant that helps manage ADHD symptoms. Dougherty added that Teva expects “intermittent delays through end of year.”The supply from the other Adderall manufacturers isn’t enough to meet the need, the FDA said. The shortage has hit pharmacies differentlySome pharmacies have been having trouble filling Adderall prescriptions since the summer. In May, Walmart and CVS announced they would stop filling prescriptions for controlled substances from telehealth startups such as Cerebral and Done Health, which prescribe stimulants and gained footing during the pandemic.

☆ An Adderall shortage is forcing some people with ADHD to reduce their work responsibilities, report says
▼ + stars: | 2022-09-18 | by ( Ryan Hogg | ) www.businessinsider.com time to read: +3 min

Some retailers including Walgreens are facing problems getting enough Adderall, Bloomberg reported. The shortage has forced some people with ADHD to pare back their duties at work. "There are supply chain challenges with this drug," Walgreens spokesperson Rebekah Pajak told Bloomberg. Anthony Anderson told Bloomberg he too was struggling to maintain his productivity at work. Another person called Kyle told BuzzFeed he was concerned about how his work performance would be affected without Adderall.

☆ Lumea va cheltui 157 de miliarde de dolari pentru vaccinuri COVID-19 până în 2025
▼ + stars: | 2021-05-01 | by ( ) www.jurnal.md time to read: +3 min

Sursa foto: Jurnal.mdLumea va cheltui 157 de miliarde de dolari pentru vaccinuri COVID-19 până în 2025Cheltuielile globale totale pentru vaccinuri COVID-19 sunt prognozate să ajungă la 157 miliarde de dolari până în 2025, stimulate de programele de vaccinare în masă care sunt în derulare şi rapelurile care ar urma să fie făcute odată la doi ani, arată un raport publicat de firma americană de consultanţă IQVIA Holdings, transmite Reuters. IQVIA, care furnizează date şi analize pentru industria de sănătate, se aşteaptă ca primul val de vaccinuri COVID-19 să ajungă la aproximativ 70% din populaţia lumii până la finele lui 2022. Cheltuielile preconizate pentru vaccinurile COVID-19 reprezintă 2% din cele aproximativ 7.000 de miliarde de dolari reprezentând cheltuielile preconizate pentru toate medicamentele pe bază de reţetă până în 2025. Raportul IQVIA adaugă că dacă ar fi excluse costurile cu vaccinurile COVID-19, cheltuielile totale cu medicamentele în perioada 2020-2025 ar fi fost cu 68 de miliarde de dolari mai mici decât ar fi fost fără pandemie. "Chiar dacă vaccinurile COVID-19 vor costa 157 de miliarde de dolari în următorii cinci ani, acesta este un preţ foarte mic de plătit comparativ cu costul uman al pandemiei", subliniază Murray Aitken.

Persons: Murray Aitken, susţine Aitken Organizations: americană, Reuters, Albă, Pfizer, Agerpres Locations: Holdings, SUA

☆ Lumea va cheltui 157 miliarde de dolari pentru vaccinuri anti-COVID până în 2025
▼ + stars: | 2021-04-29 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +3 min

IQVIA, care furnizează date şi analize pentru industria de sănătate, se aşteaptă ca primul val de vaccinuri COVID-19 să ajungă la aproximativ 70% din populaţia lumii până la finele lui 2022. Cel mai probabil, rapelurile vor urma vaccinărilor iniţiale odată la doi ani, pe baza datelor disponibile în prezent cu privire la durata efectului vaccinurilor. Cheltuielile preconizate pentru vaccinurile COVID-19 reprezintă 2% din cele aproximativ 7.000 de miliarde de dolari reprezentând cheltuielile preconizate pentru toate medicamentele pe bază de reţetă până în 2025. Raportul IQVIA adaugă că dacă ar fi excluse costurile cu vaccinurile COVID-19, cheltuielile totale cu medicamentele în perioada 2020-2025 ar fi fost cu 68 de miliarde de dolari mai mici decât ar fi fost fără pandemie. "Chiar dacă vaccinurile COVID-19 vor costa 157 de miliarde de dolari în următorii cinci ani, acesta este un preţ foarte mic de plătit comparativ cu costul uman al pandemiei", subliniază Murray Aitken.

Persons: Murray Aitken, susţine Aitken Organizations: americană, Reuters, Albă, Pfizer Locations: Holdings, SUA

IQVIA, care furnizează date şi analize pentru industria de sănătate, se aşteaptă ca primul val de vaccinuri Covid-19 să ajungă la aproximativ 70% din populaţia lumii până la finele lui 2022. Cel mai probabil, rapelurile vor urma vaccinărilor iniţiale odată la doi ani, pe baza datelor disponibile în prezent cu privire la durata efectului vaccinurilor. Cheltuielile preconizate pentru vaccinurile Covid-19 reprezintă 2% din cele aproximativ 7.000 de miliarde de dolari reprezentând cheltuielile preconizate pentru toate medicamentele pe bază de reţetă până în 2025. Raportul IQVIA adaugă că dacă ar fi excluse costurile cu vaccinurile Covid-19, cheltuielile totale cu medicamentele în perioada 2020-2025 ar fi fost cu 68 de miliarde de dolari mai mici decât ar fi fost fără pandemie. „Chiar dacă vaccinurile Covid-19 vor costa 157 de miliarde de dolari în următorii cinci ani, acesta este un preţ foarte mic de plătit comparativ cu costul uman al pandemiei”, subliniază Murray Aitken.

Persons: Murray Aitken, susţine Aitken Organizations: Albă, Pfizer Locations: SUA

☆ Opioid Crisis Fast Facts
▼ + stars: | 2017-09-18 | by ( Cnn Editorial Research | ) edition.cnn.com time to read: +15 min

March 29, 2017 - Trump signs an executive order calling for the establishment of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. April 9, 2018 - The US surgeon general issues an advisory recommending that Americans carry the opioid overdose-reversing drug, naloxone. The settlement will be used to fund addiction research and help cities and counties with the opioid crisis. Cleveland County District Judge Thad Balkman orders Johnson & Johnson to pay $572 million for its role in the state’s opioid crisis. November 15, 2022 - Walmart agrees to the framework of a $3.1 billion settlement, which resolves allegations from multiple states’ attorneys general that the company failed to regulate opioid prescriptions contributing to the nationwide opioid crisis.

Search resuls for: "Iqvia"

17 mentions found